Jeffrey Hollins

Jeffrey Hollins has a diverse work experience in the field of protein sciences and biophysical research. Jeffrey is currently working as the Head of Protein Sciences at T-Therapeutics Ltd since April 2023. Before that, they served as a Senior Research Scientist 1 at Kymab Ltd from August 2017 to April 2023.

Jeffrey's earlier experience includes working as a Research Associate at the University of Cambridge from November 2013 to July 2017. During their time there, they investigated the biophysical characteristics of cotranslational protein folding using various techniques and collaborations.

Prior to that, they served as a Postdoctoral Fellow at the University of Edinburgh from September 2012 to July 2013, where they focused on engineering redox proteins and controlled protein aggregation.

Jeffrey also gained valuable experience during their PhD studies at the University of Leeds from October 2008 to October 2012, where they studied the mechanistic properties of E. coli YdiA and plant pectin methylesterase inhibitors.

Their earlier roles include a Wellcome Trust Placement at The Paterson Institute for Cancer Research, where they worked on overexpression and partial characterization of a novel DNA repair enzyme, and a BSc Studentship at Lancaster University, studying the effect of short chain oligopeptides on alpha-chymotrypsin activity.

Overall, Jeffrey Hollins has a strong background in protein sciences and biophysical research, with experience in leadership roles, collaborative projects, and diverse research areas.

Jeffrey Hollins has a strong educational background in biochemistry and genetics. Jeffrey obtained their Bachelor of Science (BSc) Hons degree in Biochemistry with Genetics from Lancaster University in 2007. Following this, they pursued a Master of Science (MSc) degree in Chemical Biology at the University of Leeds from 2007 to 2008. Jeffrey then furthered their education by completing a Doctor of Philosophy (PhD) in Biochemistry from the University of Leeds, which took place from 2008 to 2012. Based on this information, it can be inferred that Jeffrey Hollins has a solid foundation in the field of biochemistry and genetics.